NICE Turnaround On Novartis' Xolair To Be Discussed At Asthma & Copd Conference, 15-16 April 2013, London

The UK's National Institute for Health and Clinical Excellence (NICE) has recently recommended Xolair, Novartis as an option for treating severe, persistent allergic asthma in adults, adolescents and children. The decision comes as a result of a move by Novartis to offer a patient access scheme to discount Xolair's list price. An estimated 65 million people currently suffer from COPD globally with 300 million asthma sufferers...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Conferences Source Type: news